levofloxacin has been researched along with isoniazid in 89 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | levofloxacin (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.37) | 18.2507 |
| 2000's | 12 (13.48) | 29.6817 |
| 2010's | 57 (64.04) | 24.3611 |
| 2020's | 17 (19.10) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Gan, M; Guan, Y; Liu, Y; Xiao, C; Zheng, X | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M | 1 |
| Guo, H; Li, L; Liu, M; Lu, Y; Shen, W; Wang, B; Wang, M; Zhang, R; Zhang, T | 1 |
| Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J | 1 |
| Chandrasekaran, B; Hampannavar, GA; Karpoormath, R; Palkar, MB; Shaikh, MS | 1 |
| Cui, S; Ding, K; Franzblauc, SG; Lu, X; Tang, J; Wan, B; Zhang, T; Zhang, X | 1 |
| Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Abay, E; Axtman, M; Ballell, L; Barry, CE; Boesche, M; Boshoff, HIM; Brunschwig, C; Chibale, K; Drewes, G; Gessner, RK; Ghidelli-Disse, S; Ghorpade, SR; Gordon, R; Harris, CJ; Lafuente-Monasterio, MJ; Lawrence, N; Lelièvre, J; Mizrahi, V; Moosa, A; Mueller, R; Nchinda, A; Njoroge, M; Pflaumer, H; Rebollo-Lopez, MJ; Santos, G; Sanz, O; Seldon, R; Selenski, C; Simelane, SB; Sirgel, FA; Soares de Melo, C; Street, LJ; Taylor, D; Urones, B; van Helden, P; Warner, DF; Wilson, CR | 1 |
| Ahmad, Z; Amin, S; Bhat, BA; Bhat, ZS; Dar, MJ; Lone, AM; Maqbool, M; Rather, MA; Shairgojray, BA; Singh, P; Teli, B; Yousuf, SK | 1 |
| Ahmad, Z; Ara, T; Bhat, ZS; Maqbool, M; Rather, MA; Ul Lah, H; Yousuf, SK | 1 |
| Borra, RS; Chopra, S; Das, S; Dasgupta, A; Gatadi, S; Gour, J; Kaul, G; Madhavi, YV; Malasala, S; Nanduri, S; Shukla, M | 1 |
| Chopra, S; Dusthackeer, VNA; Krishna, EV; Krishna, VS; Mahizhaveni, B; Makane, VB; Misra, S; Rode, HB; Shukla, M; Sriram, D | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Bera, S; Mondal, D | 1 |
| Kalra, S; Khatik, GL; Kumar, GN; Kumar, R; Narang, R; Nayak, SK; Singh, SK; Sudhakar, K | 1 |
| Mabhula, A; Singh, V | 1 |
| Ahmad, MN; Akunuri, R; Chopra, S; Dasgupta, A; Kaul, G; Madhavi, YV; Malasala, S; Nanduri, S; Shukla, M | 1 |
| Bishai, WR; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Wang, SS; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Batt, SM; Besra, GS; Fu, L; Huang, H; Li, G; Lu, Y; Qin, R; Wang, B; Wang, P; Wang, Y; Wu, C | 1 |
| Chopra, S; Dasgupta, A; Kaul, G; Kumar Sahoo, S; Maddipatla, S; Madhavi Yaddanapudi, V; Nageswara Rao Gajula, S; Naiyaz Ahmad, M; Nanduri, S; Sonti, R | 1 |
| Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C | 1 |
| Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE | 1 |
| Chirgwin, KD; Cohn, DL; el-Sadr, WM; Hafner, R; Heifets, L; Jones, BE; Klein, O; Matts, JP; Medard, F; Mildvan, D; Nelson, ET; Olibrice, M; Perlman, DC; Salomon, N; Telzak, EE | 1 |
| Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS | 1 |
| Bogadel'nikova, IV; Kunichan, AD; Semenova, OV; Sokolova, GB | 1 |
| Aguilar, R; Auclair, B; Maslow, JN; Mikota, SK; Peloquin, CA | 1 |
| Kunichan, AD; Litovchenko, KV; Sokolova, GB; Tsybanev, AA | 1 |
| Li, SM; Xing, BC; Zheng, XM | 1 |
| Bhusal, Y; Shiohira, CM; Yamane, N | 1 |
| Cappelletty, DM | 1 |
| Chen, YH; Eng, HL; Huang, CK; Lai, CH; Lin, HF; Lin, HH; Lin, JN | 1 |
| Cai, HL; Chen, YC; Fang, PF; Gao, W; Li, HD; Liu, YP; Tan, QY; Xu, P; Zhang, F; Zhang, WY; Zhu, RH | 1 |
| Caminero, JA; Migliori, GB; Sotgiu, G; Zumla, A | 1 |
| Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Akçalı, A; Akman, T; Değirmenci, Y; Karatağ, O; Koşar, S; Sener, A | 1 |
| Bergmann, JF; Cambau, E; Evans, J; Hoang-Nguyen, DT; Lloret-Linares, C; Lopes, A; Mouly, S; Raskine, L; Sellier, P | 1 |
| Chikamatsu, K; Fujita, A; Matsumoto, T; Mitarai, S; Mizuno, K; Ogata, H; Saito, T; Suetake, T; Suzuki, K; Toyota, E | 1 |
| Cataldi, AA; Di Giulio, AB; Imperiale, BR; Morcillo, NS; Zumárraga, MJ | 1 |
| Denno, K; Horiki, M; Minoda, Y; Tada, K; Yano, K; Yoneda, M; Yoshida, T | 1 |
| Chandrasekaran, V; Dewan, P; Hemanth Kumar, AK; Ramachandran, G; Swaminathan, S; Thomas, A | 1 |
| Caleffi-Ferracioli, KR; Cardoso, RF; Maltempe, FG; Siqueira, VL | 1 |
| Bhoi, SK; Kalita, J; Misra, UK; Prasad, S | 1 |
| Adrián Cataldi, A; Di Giulio, ÁB; Imperiale, BR; Morcillo, NS | 1 |
| Arai, M | 1 |
| Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
| Alling, T; Bailey, MA; Casey, A; Early, JV; Files, M; Gonzalez Valcarcel, IC; Martinez-Grau, MA; Ollinger, J; Ovechkina, Y; Parish, T; Vieth, M | 1 |
| Betai, S; Bhoi, SK; Kalita, J; Misra, UK | 1 |
| Choi, JH; Heo, NY; Jo, KM; Kim, WG; Nam, KH; Park, CS; Park, SH | 1 |
| Juthong, S; Laohapojanart, N; Padmavathi, AR; Pungrassami, P; Ratanajamit, C; Srichana, T; Suwandecha, T | 1 |
| Khanna, SR; Kralovic, SM; Prakash, R | 1 |
| Du, J; Gao, J; Gao, M; Li, L; Liu, Y; Ma, L; Mi, F; Tang, S; Zhang, Y | 1 |
| Aono, A; Chikamatsu, K; Igarashi, Y; Mitarai, S; Takaki, A; Yamada, H; Yi, L | 1 |
| Jung, BH; Lee, SG; Park, JI | 1 |
| Baldin, VP; Caleffi-Ferracioli, KR; Campanerut-Sá, PAZ; Cardoso, RF; de Almeida, AL; Nakamura de Vasconcelos, SS; Santos, NCS; Scodro, RBL; Siqueira, VLD | 1 |
| Boulle, A; Fox, T; Khomo, N; Kock, Y; Leslie, J; Manning, K; Meintjes, G; Mudaly, V; Stewart, A; Tiffin, N; Wasserman, S; Zhao, Y | 1 |
| Patel, S; Roy, S; Weaver, MD | 1 |
| Bendet, P; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S | 1 |
| Alarcón Guizado, VA; Alarcon, E; Cornejo Garcia, JG; Heldal, E; Mendoza Ticona, A; Moore, DAJ | 1 |
| Abbara, A; Abubakar, I; Alexander, E; Booth, H; Bothamley, GH; Creer, DD; Davidson, JA; Harris, RJ; Kon, OM; Kunst, H; Lalor, MK; Lipman, MC; Loebinger, MR; Loutet, MG; Lozewicz, S; McHugh, TD; Milburn, HJ; Mohiyuddin, T; Palchaudhuri, P; Phillips, PPJ; Schmok, E; Stagg, HR; Taylor, L | 1 |
| Caleffi-Ferracioli, KR; Cardoso, RF; Costacurta, GF; da Silva, LA; de Almeida, AL; de Pádua, RA; do Prado, SM; Ghiraldi Lopes, LD; Ieque, AL; Leal, DC; Micheletti, DF; Sampiron, EG; Santos, NCS; Scodro, RBL; Siqueira, VL | 1 |
| Baloch, AQ; Ghazal, A; Khanzada, FM; Mustafa, T; Qadir, M; Rizvi, AH; Tahseen, S | 1 |
| Eather, G; Matigian, N; O'Connor, B; Wilson, M | 1 |
| Borroni, E; Cambau, E; Cirillo, DM; Giske, C; Kahlmeter, G; Lina, G; Machado, D; Matuschek, E; Mouton, J; Santin, M; Schön, T; Viveiros, M; Werngren, J; Wijkander, M | 1 |
| Agejeva, A; Altraja, A; Klaos, K; Kummik, T; Laks, S; Remets, O; Sasi, S; Tann, A; Viiklepp, P | 1 |
| Ishikawa, S; Mukai, Y; Paudel, S; Suga, S; Wada, T; Yoshida, S | 1 |
| Davies, GR; Peloquin, CA | 1 |
| Kawkitinarong, K; Laohapojanart, N; Ratanajamit, C; Srichana, T | 1 |
| Leung, PKL; Ng, KKM; Yip, PCW | 1 |
| Alarcón, MJ; Coronel, J; Cotrina, VV; Moore, DAJ; Puyén, ZM; Santos-Lázaro, D; Vigo, AN | 1 |
| Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N | 1 |
| Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
6 review(s) available for levofloxacin and isoniazid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Recent advancements in mechanistic studies and structure activity relationship of F
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium; Proton-Translocating ATPases; Structure-Activity Relationship | 2019 |
Drug-resistance in
Topics: | 2019 |
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Levofloxacin; Ofloxacin; Pyrazinamide; Tuberculosis | 2010 |
The Treatment of Tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Isoniazid; Levofloxacin; Rifampin; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
9 trial(s) available for levofloxacin and isoniazid
| Article | Year |
|---|---|
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; In Vitro Techniques; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sputum; Tuberculosis | 1997 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Recurrence; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2004 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspirin; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Prednisolone; Pyrazinamide; Radiography; Rifampin; Treatment Outcome; Tuberculosis, Meningeal; Young Adult | 2014 |
Safety and efficacy of additional levofloxacin in tuberculous meningitis: A randomized controlled pilot study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Disability Evaluation; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Pyrazinamide; Rifampin; Seizures; Time Factors; Treatment Outcome; Tuberculosis, Meningeal; Young Adult | 2016 |
Evaluation of Proinflammatory Cytokines and Adverse Events in Healthy Volunteers upon Inhalation of Antituberculosis Drugs.
Topics: Administration, Inhalation; Adult; Antitubercular Agents; Cross-Over Studies; Double-Blind Method; Dry Powder Inhalers; Female; Healthy Volunteers; Humans; Interleukin-1beta; Isoniazid; Levofloxacin; Liposomes; Male; Peak Expiratory Flow Rate; Pyrazinamide; Rifampin; Sputum; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Ethambutol; Female; Humans; Infant; Infant, Newborn; Isoniazid; Levofloxacin; Male; Middle Aged; Peru; Pyrazinamide; Retrospective Studies; Rifampin; Sex Factors; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.
Topics: Dry Powder Inhalers; Humans; Isoniazid; Levofloxacin; Powders; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2021 |
74 other study(ies) available for levofloxacin and isoniazid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Three new 12-carbamoylated streptothricins from Streptomyces sp. I08A 1776.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; Fungi; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Stereoisomerism; Streptomyces; Streptothricins | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship | 2014 |
Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enterococcus; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrrolidines; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2015 |
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism | 2015 |
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes | 2016 |
Dehydrozingerone Inspired Styryl Hydrazine Thiazole Hybrids as Promising Class of Antimycobacterial Agents.
Topics: | 2016 |
Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridines | 2017 |
The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.
Topics: Amines; Antitubercular Agents; Dose-Response Relationship, Drug; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Parasitic Sensitivity Tests; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Trypanosoma cruzi | 2017 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.
Topics: Administration, Oral; Animals; Antitubercular Agents; Blood Proteins; Drug Stability; High-Throughput Screening Assays; Humans; Male; Mice, Inbred C57BL; Microsomes, Liver; Mycobacterium tuberculosis; Proteomics; Pyrimidines; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents.
Topics: | 2017 |
Synthesis and
Topics: | 2018 |
Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinazolinones; Staphylococcal Infections; Structure-Activity Relationship; Triazoles | 2018 |
Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.
Topics: Amides; Animals; Antitubercular Agents; Cell Line; Chemistry, Pharmaceutical; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship | 2021 |
Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.
Topics: Antitubercular Agents; Bacterial Proteins; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Polyketide Synthases; Quinolones; Structure-Activity Relationship | 2021 |
Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Benzenesulfonamides; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship; Sulfonamides; Thiophenes; Tuberculosis, Multidrug-Resistant | 2022 |
Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.
Topics: Amines; Animals; Antitubercular Agents; Benzoxazoles; Chlorocebus aethiops; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitrofurans; Tuberculosis; Tuberculosis, Multidrug-Resistant; Vero Cells | 2022 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Isomerism; Isoniazid; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Splenomegaly; Survival Rate; Tuberculosis | 1995 |
A whole blood bactericidal assay for tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin | 2001 |
[Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Cell Movement; Culture Techniques; Drug Interactions; Drug Resistance, Multiple, Bacterial; Isoniazid; Levofloxacin; Lung; Lymphocytes; Macrophages; Mice; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin | 2002 |
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Topics: Amikacin; Animals; Antelopes; Antitubercular Agents; Area Under Curve; Ethambutol; Female; Isoniazid; Levofloxacin; Male; Mycobacterium bovis; Ofloxacin; Pyrazinamide; Rifampin; Tuberculosis | 2002 |
[Evaluation of levofloxacin antitubercular activity in vitro and in lung tissue culture].
Topics: Anti-Infective Agents; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide | 2002 |
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Drug Synergism; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Tuberculosis | 2005 |
Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.
Topics: Antitubercular Agents; Cell Line; Half-Life; Humans; Isoniazid; Levofloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin | 2007 |
Urinary Mycobacterium szulgai infection in an immunocompetent patient.
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Immunocompetence; Isoniazid; Levofloxacin; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Rifampin; Urinary Tract Infections | 2009 |
Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Animals; Antibiotics, Antitubercular; Brain Chemistry; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gatifloxacin; Intestine, Small; Isoniazid; Kidney; Least-Squares Analysis; Levofloxacin; Liver; Lung; Male; Methanol; Mice; Ofloxacin; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
[Epidural abscess due to a Mycobacterium tuberculosis strain with primary resistance to isoniazid and ethambutol].
Topics: Antitubercular Agents; Cervical Vertebrae; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Epidural Abscess; Ethambutol; Humans; Isoniazid; Levofloxacin; Magnetic Resonance Imaging; Male; Middle Aged; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Streptomycin; Thoracic Vertebrae; Tuberculosis, Central Nervous System | 2012 |
Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with Mycobacterium bovis infection.
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Isoniazid; Levofloxacin; Male; Mycobacterium bovis; Ofloxacin; Overweight; Practice Guidelines as Topic; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Lymph Node | 2013 |
[Clinical evaluation of a line probe assay kit for the identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis].
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin | 2013 |
Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
Topics: Antitubercular Agents; Argentina; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Rifampin; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Clinical outcome of the chronic flexor tenosynovitis in the hand caused by non-tuberculous mycobacterium treated by extensive tenosynovectomy and drugs.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Hand; Hand Strength; Humans; Immunocompetence; Isoniazid; Levofloxacin; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Mycobacterium marinum; Osteomyelitis; Range of Motion, Articular; Retrospective Studies; Rifampin; Scaphoid Bone; Synovectomy; Tenosynovitis | 2013 |
Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
Topics: Antitubercular Agents; Cycloserine; Drug Stability; Drug Storage; Drug Therapy, Combination; Ethambutol; Ethionamide; Humans; India; Isoniazid; Levofloxacin; Ofloxacin; Pyrazinamide; Rifampin; Spectrophotometry; Tuberculosis | 2013 |
Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ethambutol; Humans; Indicators and Reagents; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Oxazines; Tuberculosis; Tuberculosis, Multidrug-Resistant; Xanthenes | 2013 |
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Rifabutin; Rifampin; Sequence Analysis, DNA; Tuberculosis | 2014 |
[A case of tuberculous meningitis complicated with multiple drug hypersensitivity to antituberculosis agents].
Topics: Antitubercular Agents; Drug Hypersensitivity; Drug Therapy, Combination; Ethambutol; Ethionamide; Humans; Immunologic Tests; Isoniazid; Levofloxacin; Lymphocyte Activation; Male; Middle Aged; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Meningeal | 2015 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Oxadiazoles Have Butyrate-Specific Conditional Activity against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Butyric Acid; Cell Survival; Chlorocebus aethiops; Culture Media; Glucose; High-Throughput Screening Assays; Isoniazid; Kanamycin; Levofloxacin; Metabolic Networks and Pathways; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxadiazoles; Small Molecule Libraries; Species Specificity; Structure-Activity Relationship; Vero Cells | 2016 |
[Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid].
Topics: Alanine Transaminase; Antitubercular Agents; Cycloserine; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Eosinophilia; Ethambutol; Female; Hepatitis, Autoimmune; Humans; Isoniazid; Levofloxacin; Liver; Prothionamide; Severity of Illness Index; Tuberculosis; Young Adult | 2016 |
Tuberculous Meningitis in an Immunocompetent Host: A Case Report.
Topics: Antitubercular Agents; Cerebrospinal Fluid; Drug Therapy, Combination; Emigrants and Immigrants; Humans; Immunocompetence; Isoniazid; Levofloxacin; Male; Middle Aged; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Senegal; Treatment Outcome; Tuberculosis, Meningeal; United States | 2016 |
Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Rifampin; Sensitivity and Specificity; Seoul; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2017 |
Urgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report.
Topics: Antitubercular Agents; Humans; Isoniazid; Levofloxacin; Liver Failure; Liver Transplantation; Living Donors; Male; Middle Aged; Rifampin; Tuberculosis | 2018 |
Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Isoniazid; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; HIV; HIV Infections; Humans; Isoniazid; Isoxazoles; Levofloxacin; Male; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Retrospective Studies; South Africa; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Miliary tuberculosis and herpes pharyngitis after a trip to a developing country: dangers of biologics.
Topics: Adalimumab; Aged, 80 and over; Anti-Bacterial Agents; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Biological Products; Developing Countries; Diagnosis, Differential; Herpes Simplex; Herpesvirus 1, Human; Humans; India; Isoniazid; Levofloxacin; Lung; Male; Opportunistic Infections; Pharyngitis; Pyrazinamide; Tomography, X-Ray Computed; Travel-Related Illness; Tuberculin Test; Tuberculosis, Miliary; Vitamin B 6 | 2018 |
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Ethionamide; Humans; Isoniazid; Levofloxacin; Monte Carlo Method; Mutation; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Logistic Models; London; Male; Middle Aged; Practice Guidelines as Topic; Pyrazinamide; Recurrence; Retrospective Studies; Rifampin; Treatment Failure; Tuberculosis, Multidrug-Resistant; World Health Organization; Young Adult | 2019 |
Determination of minimum bactericidal concentration, in single or combination drugs, against
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Isoniazid; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2020 |
Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Epidemiological Monitoring; Female; Genotype; Humans; Infant; Isoniazid; Laboratories; Levofloxacin; Male; Microbial Sensitivity Tests; Pakistan; Phenotype; Pyrazinamide; Retrospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Australia; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; Ethinyl Estradiol-Norgestrel Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Bacteriological Techniques; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Reproducibility of Results | 2021 |
A successful introduction to a non-expert setting of the thin-layer agar Colour Test as an indirect phenotypic drug susceptibility test for Mycobacterium tuberculosis.
Topics: Agar; Antitubercular Agents; Color; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Observer Variation; Rifampin; Sensitivity and Specificity | 2021 |
INTENSIVE TREATMENT OF A CAPTIVE BORNEAN ELEPHANT (
Topics: Administration, Rectal; Animals; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Elephants; Isoniazid; Japan; Levofloxacin; Mycobacterium; Mycobacterium Infections; Pyrazinamide | 2021 |
Prevalences of levofloxacin resistance and
Topics: Amidohydrolases; Antitubercular Agents; Hong Kong; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Prevalence; Tuberculosis, Multidrug-Resistant | 2021 |
Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.
Topics: Antitubercular Agents; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peru; Rifampin; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant | 2022 |
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Male; Meropenem; Micafungin; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Rifampin; Streptomycin; Teicoplanin; Tetrazoles; Tuberculosis | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2022 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |